VISTIDE TREATMENT FOR RELAPSING CMV RETINITIS IN PATIENTS WITH AIDS

接受治疗艾滋病患者复发性巨细胞病毒视网膜炎

• 批准号: 6122108
• 负责人: BRUCE A BARRON
• 金额: $ 1.12万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-19 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122108
• 关键词: AIDS; antiviral agents; clinical research; cytomegalovirus; eye disorder chemotherapy; human subject; human therapy evaluation; opportunistic infections; relapse /recurrence; retinitis

The Vistide treatment for Relapsing Cytomegalovirus Retinitis in patients with AIDS is a research study designed to: 1) make intravenous Vistide more broadly available to patients with CMV retinitis who cannot tolerate, or have progressed despite treatment with Ganciclovir and/or foscarnet, and 2) gather additional information about the safety and effectiveness of intravenous Vistide in the treatment of relapsing CMV retinitis in patients with AIDS. Patients with AIDS are at high risk for reactivation of CMV. CMV infection may be asymptomatic. However, CMV may progress and cause severe and potentially disabling damage to the lungs, gastrointestinal tract and the retina of the eye.

Vistide 治疗艾滋病患者复发性巨细胞病毒视网膜炎是一项研究，旨在：1) 使静脉注射 Vistide 更广泛地适用于无法耐受或在接受更昔洛韦和/或膦甲酸治疗后病情仍出现进展的 CMV 视网膜炎患者，以及 2)收集有关静脉注射 Vistide 治疗艾滋病患者复发性巨细胞病毒视网膜炎的安全性和有效性的更多信息。 艾滋病患者 CMV 重新激活的风险很高。 CMV 感染可能无症状。 然而，巨细胞病毒可能会发展并对肺部、胃肠道和眼睛视网膜造成严重且可能致残的损害。